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Abstract
Background: Human papillomavirus (HPV) serology is a main factor for designing vaccination programs and
surveillance strategies; nevertheless, there are few reports of HPV seroprevalence in the general population, especially
in Latin America. This study aimed to describe high-risk HPV serological prevalence, persistence, and association with
concurrent cervical infection, in Chilean women.
Methods: 1021 women from the general population, aged 15–85 years, were studied in 2001 of whom 600 were
reexamined in 2006. The assessments at both time points included cervical HPV DNA testing, HPV antibody testing,
cervical cytology and a sociodemographic/behavioral questionnaire. HPV DNA and antibodies against L1 protein of
types 16, 18, 31, 33, 35, 45, 52, and 58 were assessed by reverse line blot and multiplex serology, respectively.
Results: Seropositivity was high at both baseline (43.2%) and follow-up (50.2%) and increased with age (p < 0.001);
corresponding DNA prevalences were 6.7% and 8.7%. DNA and seroprevalence were associated at baseline (p = 0.01
for any HPV). Early age at first sexual intercourse and having had two or more sexual partners were independently
associated with seropositivity. Most (82.0%) initially seropositive women remained seropositive at follow-up; 21.6%
of initially seronegative women seroconverted, reaching 17.5% among women older than 60 years of age. ASCUS or
worse cytology was correlated with HPV DNA positivity but not with HPV seropositivity.
Conclusion: HPV seroprevalence studies are a useful tool for learning about the dynamics of HPV infection in a
community. This study contributes to understanding the natural history of HPV infection and provides a baseline
assessment before the incorporation of HPV vaccination into a national program.
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Background
Chile is a Latin American country where screening pro-
grams for cervical cancer have been effective in decreas-
ing the burden of this malignancy [1]. Nevertheless,
1478 women are diagnosed with cervical cancer and ap-
proximately 600 die from the disease every year in Chile.
Age-standardized cervical cancer mortality rate of 5.7/
100,000 [2] in Chile is still substantially higher than the
rates reported in the majority of developed countries
[3,4]. Women with low socio-economic status are most
affected by this disease [5].
Human papillomavirus (HPV) is the most common
sexually transmitted infection in the world and persistent
infection with high-risk HPV (HR-HPV) types is a neces-
sary cause of cervical cancer [6]. A population-based sur-
vey of adult Chilean women reported an overall prevalence
of HR-HPV genital infection (any oncogenic type) of 15%,
with the highest prevalence observed in women under
25 years old [7]. A subsequent study confirmed that,
among women in Santiago, Chile, cervical infection with
HR-HPV peaks at young ages (< 20 years old) and then
steadily decreases to stabilize around age 40 years, and in-
creases again after age 60 years [8].
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While HPV DNA informs about current cervical infec-
tion, incident or persistent, it is not a marker for cumula-
tive exposure to the virus [9]. Cumulative exposure is best
determined by measurement of serum IgG antibodies
against HPV, which are considered the footprints left by
infections that occurred during the lifetime of the indi-
viduals because they persist after DNA becomes un-
detectable [10,11]. Although HPV serology is an imperfect
measure of past exposure since almost half of DNA-
positive women are seronegative [12,13], today it is
considered a marker of cumulative HPV infection [14].
Seroprevalence studies have been useful in understanding
the natural history of HPV infection and in evaluating
HPV exposure in the population to identify target groups
for HPV vaccination programs. Also, the recommendation
of HPV immunization in girls is based on “immunological
bridging”, that is, the demonstration of similar or higher
antibody levels in girls as in women in whom clinical effi-
cacy against cervical carcinoma in situ was shown [15];
and the duration of vaccine protection and the need of
a booster dose will be based partly on serological sur-
veillance of HPV antibodies. In particular, multiplex as-
says for detection of antibodies against several HPV types
have an interesting potential in epidemiologic studies;
evaluations of such methods in prospective cohorts pro-
vide additional information about the utility of seroassays
and about the serologic response to HPV infection in spe-
cific populations.
As part of a population-based study of the natural his-
tory of HPV infection in women from Santiago, Chile
[8,16], we evaluated here seroprevalence and seropersis-
tence and their correlates for the eight most common




The present analysis was performed on a random sample
of 1393 Chilean women from the general population of
a low socio-economic area of Santiago, Chile. A detailed
description of the study design, enrollment, data collec-
tion procedures and results of HPV DNA infection has
been published previously [16]. Briefly, eligible women
were those aged 15 years and older, who were sexually
active, not pregnant, covered by the national health in-
surance system and who had no medical impediment to
participate. Women were examined at enrollment in
2001 and follow-up in 2006; assessment at both time
points included Pap cytology, cervical HPV DNA testing,
HPV antibody testing and a sociodemographic and be-
havioral questionnaire [8]. A total of 1221 (87.6%) agreed
to participate at baseline and 689 (56.4%) of them par-
ticipated at follow-up. Causes of non-participation in
follow-up have been reported elsewhere [8]. The analysis
of seroprevalence was restricted to 1021 women who had
complete serologic data at baseline, and the analysis of
seropersistence to 600 women who had serological results
for both baseline and follow-up visits. Participants who
completed follow-up were slightly different from those
who did not: they were more likely to have a low education
level, to be single and to have fewer children and fewer
sexual partners at baseline; however, they had similar any
HPV DNA prevalence (5.9% and 7.5% respectively), any
HPV seroprevalence (44.5% and 41.6% respectively),
proportion of seropositive women with multiple HPV
types (42.3% and 48.6% respectively) and prevalence of
ASCUS or worse (ASCUS+) cytology (3.7% both groups)
(Additional file 1).
All participants gave written informed consent. The
study protocol was approved by the ethical committees
of the Ministry of Health’s South-Eastern Health Service
and of the International Agency for Research on Cancer.
Sample collection
Collection of cervical samples for HPV DNA testing has
been described previously [8,16]. Briefly, women attended
a health center where a midwife collected exfoliated cer-
vical cells using an Ayre spatula which was then placed in
a tube with PBS; additionally, a spatula and cytobrush used
for a Pap smear obtained at the same visit were washed in
this tube. The samples were centrifuged at 3,000 × g for
10 minutes and the resulting pellet was diluted in saline
solution and stored at -30°C until sent for analysis. A
10 ml blood sample was collected from all consenting par-
ticipants. Blood samples were centrifuged at 1500 × g for
10 min and serum was divided into different aliquots.
Serum samples were stored first at -20°C for no longer
than one week and then at -70°C until sent for analysis. A
total of 36 serum samples (18 collected in 2001 and 18 in
2006) were excluded due to insufficient sample material.
HPV DNA testing
The method used for HPV DNA testing has been described
in detail elsewhere [8,16]. Briefly, cervical samples were an-
alyzed at the Department of Pathology of the VU University
Medical Center in Amsterdam, The Netherlands. Geno-
typing was performed using a GP5+/6+ primer-mediated
PCR and enzyme immune assay. Reverse line blot geno-
typing was used to identify HR-HPV types 16, 18, 31, 33,
35, 45, 52 and 58.
HPV multiplex serology
Serum samples were analyzed at the German Cancer Re-
search Center (DKFZ), Heidelberg, Germany. The pres-
ence of IgG antibodies against the major capsid protein
L1 of HR-HPV types 16, 18, 31, 33, 35, 45, 52 and 58 was
assessed using multiplex serology based on glutathione
S-transferase fusion proteins, which has been broadly
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used in epidemiological studies [14]. The included HPV
types were selected because they are the most frequent
types in cervical cancer worldwide [17]; in Chile, they are
present in 98.3% of cervical cancers [18]. The assay was
previously described in detail [19,20]. Briefly, fluorescence-
coded bead sets (3000 beads per set per well) carrying dif-
ferent HPV antigens were mixed and incubated with
serum diluted to 1:100 in 96-well plates. The plates were
incubated on a shaker in the dark at room temperature
for one hour. The beads were washed three times with
100 ml casein buffer on a vacuum manifold. Secondary bi-
otinylated antibody and the fluorescent reporter conjugate
streptavidin-R-phycoerythrin were added and incubated
for one hour and 30 minutes, respectively, with washing
steps in between. The reporter fluorescence of the beads
was determined with a Luminex analyzer and expressed as
the median fluorescence intensity (MFI) of at least 100
beads per set per well.
Seropositivity cutoffs for each specific HPV type have
been previously defined [12,21]. Briefly, cutoffs were cal-
culated for each type based on the MFI values of serum
samples obtained from women presumed to be naïve to
HPV infections (371 female students who reported never
having engaged in penetrative sexual intercourse and
had no evidence of genital HPV DNA for 25 HPV types).
The cutoffs were defined as 5 standard deviations above
the means of this naïve group. For the present study, a
set of 186 informative “bridging” sera, with known anti-
body status, were tested with our own samples to allow
the defined cutoffs to be standardized to the exact assay
conditions of the present sample batch. Serology results
were dichotomized as antibody positive or negative.
Statistical methods
For the following analyses, “any HPV” refers to seroposi-
tivity or DNA positivity for at least one of the following
HR-HPV types: 16, 18, 31, 33, 35, 45, 52, and 58.
Any, type-specific and age-specific (< 20, 21-30, 31-40,
41-50, 51-60, and > =61 years) HR-HPV seroprevalence
(at baseline and follow-up), seropersistence, seroclearance
and seroconversion (at follow-up) were assessed. Seroper-
sistence was defined as the number of women who were
seropositive at baseline and follow-up among all women
who were seropositive at baseline. Seroclearance was the
number of women who were seropositive at baseline and
seronegative at follow-up among all those seropositive at
baseline. Seroconversion was the number of women sero-
negative at baseline and seropositive at follow-up among
those seronegative at baseline.
Baseline seropositivity was compared with concurrent
cervical DNA positivity to assess concordance, which can
only be examined at the type-specific level, as women are
often infected with multiple types of HPV and the concord-
ance status can be different for each type. To overcome
such limitation, analyses were performed at the genotype
level using generalized estimating equation (GEE) models
that account for the lack of independence between mul-
tiple observations from the same woman [22,23].
Univariable and multivariable GEE models were per-
formed to identify predictors of HR-HPV seroprevalence
at baseline. Risk estimates were adjusted by potential risk
factors for HPV seropositivity: age at baseline, marital sta-
tus, education level, number of children, age at first sexual
intercourse, lifetime number of sexual partners, high-risk
sexual partner (who engaged in extra-relationship sexual
activity), history of sexually transmitted disease, hormonal
contraception, smoking, condom use and cervical HR-
HPV DNA infection. Variables with p-value < = 0.2 in
the univariate analysis (age at baseline, age at first
intercourse, lifetime number of sexual partners, smok-
ing status, cervical HPV DNA) were then included in
multivariate models. Tests for linear trend of ORs were
performed by giving an increasing score for each level of
the categorized variable and fitting them into the model as
continuous variables. Predictors of HR-HPV seropersis-
tence were evaluated by using GEE models, as described
above for HPV seroprevalence; no variables had p-value < =
0.2 in the univariate analyses, so estimates presented were
adjusted by women’s age at baseline.
All tests were two-sided and the results with p < 0.05
were interpreted as statistically significant. Statistical ana-
lyses were performed using STATA version 11.
Results
The median age of the 1021 women studied at baseline was
43 years (range: 15-86) and for the 600 women at follow-
up it was 48 years (range: 19-87). Prevalence of ASCUS+
cytology was 3.7% (37/994) at baseline and 2.8% (16/573)
at follow-up. ASCUS+ cytology was five times more
prevalent in DNA-positive women (12.8%) than in DNA-
negative women (2.6%). On the other hand, ASCUS+
cytology was similarly prevalent in seropositive (3.6%)
and seronegative women (3.1%) (data not shown).
Cervical HR-HPV DNA positivity for at least one of the
eight studied HR-HPV types was 6.7% at baseline and
8.7% at follow-up. At baseline, the most prevalent types
were HPVs 16 (2.5%), 58 (1.3%), 31 (1.1%), 45 (0.7%) and
52 (0.7%), representing 83.3% of DNA-positive women; at
follow-up, most prevalent were HPVs 16 (3.0%), 18 (2.5%),
45 (1.7%), 31 (1.0%) and 52 (1.0%), representing 92.3% of
DNA-positive women (data not shown).
At baseline, almost half of the participants were sero-
positive for at least one of the eight studied HR-HPV
types, and seropositivity increased by 16% at follow-up
(Table 1). The four most prevalent types were HPVs 16,
18, 35 and 45, representing 88.9% of seropositive women
at baseline and 87.4% at follow-up. Nearly half of the sero-
positive women were so for multiple types at baseline and
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this proportion increased by 13% at follow-up. An analysis
restricted to only the 600 women who were followed also
shows a rise in any HPV seropositivity (13% increase, from
44.5% at baseline to 50.2% at follow-up) and in the pro-
portion of seropositive women with multiple types (19%
increase, from 42.3% at baseline to 50.5% at follow-up)
(data not shown).
Figure 1 shows any HPV and type-specific HPV sero-
prevalence and any HPV DNA prevalence by age among
all women who participated at baseline. Any HPV sero-
prevalence significantly increased with age (p-trend =
0.003); it ranged from 33.9% (age 21-30 years) to 52.6%
(age 51-60 years). Although numbers are small, type-
specific seroprevalence of the most common high-risk
types (HPV 16, 18 and 45), except for HPV 35, followed
the same trend. Any HPV DNA prevalence peaked at age
15-20 years (15.4%) declining thereafter until a second,
lower peak at age 51 to 60 years (7.6%). Type-specific
DNA curves were very unstable due to low number of in-
fections in each age category (data not shown).
At baseline, 539 (53.3%) women were negative for both
HPV DNA and antibodies, while 33 (3.3%) women were
DNA and antibody positive. Seropositivity was 50.0%
among DNA-positive women and 57.2% among DNA-
negative women (Additional file 2). Table 2 shows the
type-specific concordance between HPV DNA and HPV
antibody prevalence at baseline, considering each infec-
tion in each woman as a unit or count. Seropositivity for
each type tended to be higher among DNA-positive in-
fections with the same type, reaching statistical signifi-
cance only when all infections were analyzed together.
In summary, 17 type-specific infections coexisted with
their corresponding antibody, while 103 infections did
not.
Determinants of any HPV seropositivity at baseline are
described in Table 3. Seropositivity significantly increased
with older age, younger age at first sexual intercourse
and greater lifetime number of sexual partners. HPV DNA
positivity was also associated with seropositivity, although
not reaching statistical significance. No association was
observed with smoking status.
Among the 600 women who participated in both study
visits, 43.5% were seronegative at both visits, 8.0% (18.0%
of seropositive at baseline) presented seroclearance, 12.0%
(21.6% of seronegative at baseline) seroconverted, and
36.5% (82.0% of seropositive at baseline) presented sero-
persistence. HPV 16 seropersistence and seroconversion
were 80.5% (95% CI: 72.8-82.3) and 7.4% (95% CI: 4.8-9.2),
respectively (data not shown). Our dataset was under-
powered to detect significant differences in seropersistence
Table 1 Prevalence of high-risk human papillomavirus
antibodies among women from Santiago, Chile, at baseline
in 2001 and follow-up in 2006
Seropositivity
Baseline (n = 1021) Follow-up (n = 600)
HPV type n % (95% CI) n % (95% CI)
Any HR-HPVa 442 43.3 (40.2-46.4) 301 50.2 (46.1-54.2)
16 189 18.5 (16.2-21.0) 118 19.7 (16.5-22.9)
18 148 14.5 (12.4-16.8) 110 18.3 (15.2-21.4)
31 92 9.0 (7.3-10.9) 59 9.8 (7.4-12.2)
33 46 4.5 (3.3-6.0) 31 5.2 (3.4-6.9)
35 160 15.7 (13.5-18.0) 109 18.2 (15.1-21.3)
45 142 13.9 (11.8-16.2) 92 15.3 (12.5-18.3)
52 70 6.9 (5.4-8.6) 43 7.2 (5.1-9.2)
58 63 6.2 (4.8-7.8) 44 7.3 (5.2-9.4)
Single type 244 23.9 (21.3-26.5) 149 24.8 (21.4-29.3)
Multiple types 198 19.4 (17.0-21.8) 152 25.3 (21.8-28.8)
aPositive for at least one of the following high risk HPV types: 16, 18, 31, 33,
35, 45, 52, and 58.
HR: high-risk, HPV: human papillomavirus, CI: confidence interval.
A
B
Figure 1 Age distribution of high-risk human papillomavirus
DNA positivitya and (A) any seropositivitya or (B) type-specific
seropositivity, in 1021 women from Santiago, Chile, 2001.
aPositive for at least one of the following high-risk HPV types: 16, 18, 31,
33, 35, 45, 52, and 58. Lines represent seropositivity and bars represent
cervical DNA positivity. HR: high-risk, HPV: human papillomavirus.
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and seroconversion by age, though seropersistence was
high (74-89%) in all age groups, except for ages 15-20 years
(which had a very small sample size), and seroconversion
was between 18% and 27%, also excluding the youngest
age group (Figure 2). There were 16 women with incident
DNA infections among whom eight were seronegative at
both visits, one presented seroclearance, five presented
seropersistence and two presented seroconversion (data not
shown). Determinants of seropersistence of any HPV were
evaluated and no significant associations were identified
(Additional file 3).
Discussion
In this population-based sample of women aged 15 years
and older, from Santiago, Chile, we found a high sero-
prevalence (43%) of the eight most common HR-HPV
types; 41% of women already had antibodies at age 15-
19 years. This supports the recommendations that HPV
vaccination should begin at younger ages. Interestingly,
any HPV and type-specific seroprevalence increased with
age even at older ages, consistent with data from cross-
sectional studies in Taiwan [24], China [25], Mongolia
[21] and England [26]. However, the observed sero-
prevalence age-trend in Chile differs from reports in
the US [27,28], Costa Rica [11], The Netherlands [29]
and Australia [30], where seroprevalence peaked one or
two decades after sexual debut and steadily declined after
ages 50 or 60 years. The declining seroprevalence at older
ages is thought to be the result of the waning of antibodies
with time after HPV exposure [11]. In our Chilean popula-
tion, study participants maintained exposure to HPV in-
fection at older ages, as shown by the second peak of
DNA infection (53%) around the age of 50-60 years;
this exposure could act as a booster, maintaining high
antibody titers after age 61 years. A second HPV DNA
prevalence peak has been reported as well in other popu-
lations; however, it is not clear whether this is the re-
sult of incident infections due to new sexual partners,
the reactivation of a latent infection associated to im-
munological changes, or the result of a subgroup of the
population that had a higher exposure to HPV in their
lifetime (cohort effect) [31].
Life-time number of sexual partners, marital status,
HSV-2 infection, oral contraception, smoking and viral
Table 2 Anya and type-specific concordanceb between high-risk human papillomavirus cervical DNA positivity and






OR of seropositivity for corresponding type
(95% CI)
At woman level (n = 95)
HR-HPV other than HPV 16 51 (72.9) 19 (27.1)
HPV 16 17 (68.0) 8 (32.0) 1.3 (0.5-3.4)
HR-HPV other than HPV 18 74 (83.1) 15 (16.9)
HPV 18 5 (83.3) 1 (16.7) 1.0 (0.1-9.1)
HR-HPV other than HPV 31 73 (86.9) 11 (13.1)
HPV 31 8 (72.7) 3 (27.3) 2.5 (0.6-10.8)
HR-HPV other than HPV 33 84 (91.3) 8 (8.7)
HPV 33 2 (66.7) 1 (33.3) 5.3 (0.4-64.4)
HR-HPV other than HPV 35 74 (80.4) 18 (19.6)
HPV 35 1 (33.3) 2 (66.7) 8.2 (0.7-95.8)
HR-HPV other than HPV 45 71 (80.7) 17 (19.3)
HPV 45 6 (85.7) 1 (14.3) 0.7 (0.1-6.2)
HR-HPV other than HPV 52 76 (86.4) 12 (13.6)
HPV 52 7 (100) 0 0
HR-HPV other than HPV 58 79 (96.3) 3 (3.7)
HPV 58 12 (92.3) 1 (7.7) 2.2 (0.2-22.9)
At infection level (n = 760)
Positive to different HR-HPV 582 (85.0) 103 (15.0)
Positive to same HR-HPV 58 (77.3) 17 (22.7) 1.7 (1.1-2.5)
aAny HPV refers to HPV types 16, 18, 31, 33, 35, 45, 52, and 58.
bOnly among HPV DNA positive infections.
Bold: statistically significant results (p-value < 0.05).
HR: high-risk, HPV: human papillomavirus, OR: odds ratio, CI: confidence interval.
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load have been postulated in several studies as determi-
nants of HPV seropositivity [11,12,27,32,33]. Our ana-
lyses indicate that women who at baseline reported early
onset of sexual intercourse and two or more sexual part-
ners in their lifetime had increased odds of being seroposi-
tive; this suggests that those women were more exposed to
repeated infections, thus had higher antigenic stimulation
to develop viral antibodies. Although number of sexual
partners was associated with high seroprevalence, women
in our study reported having very few lifetime sexual part-
ners (384 and 59 women reported 2 and 3-4 partners, re-
spectively) which suggests that continuous exposure to
HPV infection may occur mostly through their current
partner. Contrary to several previous studies [12,21,27,33],
we did not observe an association of seropositivity with
marital status or high-risk sexual behavior of the part-
ner; we cannot rule out that the lack of association be-
tween HPV antibodies and high-risk partner could be
due to underreporting of this situation. Any HPV and
type-specific concordance between seropositivity and
DNA positivity was moderate, as has been reported by
others [11,12,28] and could reflect that only a subset of
women exposed to HPV will seroconvert. Baseline DNA
prevalence was significantly associated with baseline
seroprevalence (for any HR-HPV). However, it should be
noted that our concordance analysis is susceptible to be-
ing affected by cross-reactivity of the assay since we were
unable to control for this factor.
Data on the natural history of HPV antibody response
is limited; few studies report longitudinal measurements
of both DNA and antibodies. In our study, the majority
of the seropositive women at baseline were also seroposi-
tive five years later (82% for any HPV). Previous cohort
studies have shown that most women who seroconverted
remained seropositive until the end of follow-up (follow-
up periods from 18 months to 5 years) [34-36]. Observed
HPV 16 seropersistence in our study (80%) was much
higher than that reported in a large Costa Rican six-year
follow-up study (55%) of women with a similar age distri-
bution [37]; in both studies, seropersistence was constant
across different ages. A much lower seropersistence rate
(31%) was observed in the US after a minimum follow-up
of one year [38]; however this study included only young
women (mean age 20 ± 3 years). Regarding seroconver-
sion, we found a relatively high rate (21.6% for any HPV,
7% for HPV 16) with a constant pattern across age groups.
Our estimate for HPV 16 seroconversion is similar to the
one reported (6%) for Costa Rican women [37]. We must
Table 3 Determinants of seropositivity against high-risk
human papillomavirusa among 1021 women from
Santiago, Chile, 2001







≥ 61 2.16 (1.17-3.47)
p-trend < 0.001




≥ 20 0.53 (0.38-0.74)
p-trend < 0.001










aSeropositivity for at least one of the following high risk HPV types: 16, 18, 31,
33, 35, 45, 52, and 58.
bGEE estimates, odds ratios (95% confidence interval) adjusted by all variables
included in the table (variables with p-value <= 0.2 in univariate analysis).
cPositive for at least one of the following high risk HPV types: 16, 18, 31, 33,
35, 45, 52, and 58.
Bold: statistically significant (p-value < 0.05).
HPV: human papillomavirus, OR: odds ratio, CI: confidence interval.
Figure 2 Age-specific seroconversion and seropersistence of
high-risk human papillomavirus antibodies among 600 Chilean
women who participated in two cross-sectional visits (2001
and 2006). HPV types included: 16, 18, 31, 33, 35, 45, 52 and 58.
Age categories based on age at baseline. HR: high-risk, HPV:
human papillomavirus.
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note that since our study included only two assessments
five years apart, our estimates of seropersistence and sero-
conversion, although informative, could be affected by
changes that may have occurred during that interval; for
example, it is possible that women we identified as sero-
persistent in fact serocleared and later acquired a new in-
fection in the five-year period.
Limitations of the present study include the referred
lack of intermediate assessments and the relatively low
sample size that prevented us from performing more in-
formative type-specific analyses. Strengths of the study
include the population-based study design and prospect-
ive analysis, and the use of a high-throughput serologic
test that allows the simultaneous identification of anti-
bodies against eight HPV types.
Conclusions
This study provides for the first time estimates of sero-
prevalence, seropersistence and seroconversion of eight
HR-HPV types in Chile. These findings are useful to better
understand the epidemiology of the immune response to
HPV and also to inform cervical cancer prevention strat-
egies in middle developing countries in Latin-America
and elsewhere. The high HPV seroprevalence, already ele-
vated below age 20 years, as well as the increase after age
50 years support the initiation of vaccination programs at
young ages and the established screening practice at older
ages in Chile. This data constitutes a baseline assessment
before the incorporation of HPV technologies in cervical
cancer prevention.
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